← Leaderboards
Anang A Shelat
St. Jude Children'S Research Hospital
$1,872,008
Attributed
$2,774,630
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $738K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,774,630 · 2
By mechanism
R01$2,774,630 · 2
Top collaborators
- Philip M Potter2 shared
- Marcus Fischer1 shared
- William Charles Krause Pomerantz1 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Claudia Andrea Benavente$3,328,001
- John Michael Cunningham$4,118,371
- Philip M Potter$7,971,270
- Marcus Fischer$2,489,253
Others in their field
Other Emerging Leaders on “Molecular”
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,360,557
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$109,548,439
- Leonard Freedmand · Leidos Biomedical Research, Inc.$85,594,314
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Scott Hensley · University Of Pennsylvania$41,662,743
Research focus
MolecularReaderGene ExpressionMalignant NeoplasmsPharmaceutical ChemistryProteinsCellsEpigenetic ProcessIn VivoLysineNeuroblastomaNeuroblastoma CellPharmaceutical PreparationsPropertyBiologicalBromodomainCell LineDiagnosisGenerationsIn VitroChromatinLeadDesignSmall Molecule
Grant awards (6)
Targeting the chromatin binding domains of BPTF for neuroblastoma epigenetic therapy$738,024
R01 · FY2025 · CA
Bromodomain-selective inhibitors for cancer therapy$402,394
R01 · FY2023 · CA · contact PI
Bromodomain-selective inhibitors for cancer therapy$402,394
R01 · FY2022 · CA · contact PI
Bromodomain-selective inhibitors for cancer therapy$410,606
R01 · FY2021 · CA · contact PI
Bromodomain-selective inhibitors for cancer therapy$410,606
R01 · FY2020 · CA
Bromodomain-selective inhibitors for cancer therapy$410,606
R01 · FY2019 · CA